10/590794 IAP12 Rec'd PCT/PT025 AUG 2006

PATENT

Attorney Docket No. P1924US

In re Application of:

Girault et al.

Group Art Unit: Unassigned

Application No. Unassigned (U.S. National Phase of PCT/FR2005/000443)

Examiner: Unassigned

Filed: August 25, 2006

For: METHOD AND DEVICE FOR PERFORMING

A CRYPTOGRAPHIC OPERATION

INFORMATION DISCLOSURE STATEMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is material, relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

Application No. Unassigned (U.S. National Phase of PCT/FR2005/000443) of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes one of: the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below). or the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and within thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed. Copies of the References Copies of the references listed on the enclosed Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). The filing date of the subject application is after June 30, 2003. Therefore, copies of \boxtimes U.S. patents and patent applications that are listed on the accompanying Form 1449 are not enclosed herewith in accordance with the U.S. Patent and Trademark Office's waiver of the requirement under 37 CFR 1.98 (see Official Gazette Notice of August 5, 2003). Copies of other references identified on the accompanying Form 1449 are enclosed herewith. Attached to each reference not in the English language is a concise explanation of the relevance pursuant to 37 CFR 1.98(a)(3). A copy of the foreign search report is enclosed herewith. \boxtimes The references listed on the enclosed Form 1449 were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in

In re Appln. of Girault et al.

In re Appln. of Girault et al. Application No. Unassigned (U.S. National Phase of PCT/FR2005/000443)

accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

	U.S. APPLI	CATIONS	Status (check one)							
U.S	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED					
1.										
2.										
3.										
Staten	Statement under 37 CFR 1.97(e)									
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.									
	The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.									
Stater	nent under 37 CFR	1.704(d)								
	The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.									
Fees										
	No fee is owed by The IDS Fee of \$1	the applicant(s). 80 under 37 CFR 1.17(p	o) is enclosed h	erewith.						
Metho	od of Payment of F	ees								
	Charge Deposit A	k in the amount of \$. (A d	luplicate copy of					

this communication is enclosed for that purpose.)

IAP12 Rec'd PCT/PTO 25 AUG 2006

In re Appln. of Girault et al. Application No. Unassigned (U.S. National Phase of PCT/FR2005/000443)

Authorization to Charge Additional Fees

If any additional fees are owed in connection with this communication, please charge \boxtimes Deposit Account No. 07-0181. (A duplicate copy of this communication is enclosed for that purpose.)

Instructions as to Overpayment

Credit Account No. 07-0181. Refund

Brian C. Rupp, Reg. 36. 35,665 GARDNER CAR ON & DOUGLAS LLP

191 N. Wacker Drive, Suite 3700 Chicago, Illinois 60606-1698 (312) 569-1000 (telephone) (312) 569-3000 (facsimile)

Customer No.: 08968

Date: August 25, 2006

CH02/ 22460137.1

Please ty	ре а	plus	sign (+)	inside	this	box	→ :	H	_
-----------	------	------	----------	--------	------	-----	------------	---	---

IAP12 Rec'd PCT/PTO 25 AUG 2006

· · · · · · · · ·					Complete if Known		
Substitute for fo	rm 1449A/B/PTO			Application Number	Unassigned		
INIEC		DICC	N OCUPE	Filing Date August 25, 2006			
	PRMATION I			First Named Inventor	Marc GIRAULT		
STA	TEMENT BY	/ AP	PLICANT	Group Art Unit	Unassigned		
	(Use as many sheet	s as nei	cessarv)	Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	P1924US		
						•	

			_	U.S. PATENT DOCUMENTS		.,
-		U.S. Patent Do	cument	Name of Patentee or Applicant		
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code		Date of Publication	Filing Date If Appropriate
	AA	4,995,082	Α	Schnorr	February 19, 1991	
	AB	2003/0093671	A1	Owlett	May 15, 2003	
	AC	2003/0159038	A1	Gilbert et al.	August 21, 2003	
						<u> </u>
						
					-	
	ļ					
						
						-
	_		 			+
	<u> </u>	<u> </u>	 		-	
						

				FORE	IGN PATENT DOCUMENTS			<u> </u>
		Foreign Patent Document					Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	AD	FR	2 826 531	A1	France Telecom	December 27, 2002	_	X ⁺¹
·				-			<u> </u>	<u> </u>
	-			 				
				 				
	 							
			<u> </u>				1	

	OTHER - NON PATENT LITERATURE DOCUMENTS		
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		
Examiner Initials	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No**

	•		
Examiner Signature	-	Date Considered	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

¹ US 2004/0107353A1